Labanieh, Louai
Majzner, Robbie G.
Mackall, Crystal L.
Article History
Received: 20 November 2017
Accepted: 9 April 2018
First Online: 11 June 2018
Competing interests
: C.L.M. is an inventor on a patent for a CD22-directed CAR licensed by JUNO Therapeutics, receives research funding from Bluebird Bio and Obsidian Therapeutics, and serves on the advisory boards of Unum Therapeutics, GlaxoSmithKline and Vor Pharmaceuticals. L.L. and R.G.M. declare no competing interests.
Free to read: This content has been made available to all.